AstraZeneca peptide drugs include goserelin, exenatide and amylin analogs. See what the company markets, what's in the pipeline, and how to spot lookalike vendors.
AstraZeneca does not sell a product line called "peptide drugs." Its peptide-based medicines are a short list — most notably goserelin, sold as Zoladex — plus products the company acquired with Amylin Pharmaceuticals in 2012, such as exenatide and pramlintide. AstraZeneca is also testing newer peptide candidates for obesity and metabolic disease, and none of those are approved or available to the public yet.
What Counts as a Peptide Drug?
Peptides are short chains of amino acids, usually fewer than 50. That size places them between small-molecule drugs like aspirin and large biologic proteins like monoclonal antibodies.
Insulin was the first commercially successful peptide medicine, and the category now spans hormones, metabolic therapies, cancer treatments, and vaccines. Because peptides break down quickly in the digestive tract, most are given by injection rather than by mouth.
That delivery problem is one reason peptide medicines tend to be expensive, refrigerated, and prescribed rather than bought off a shelf.
AstraZeneca's Approved Peptide Medicines
AstraZeneca's peptide portfolio is small and easy to summarize. The table below covers the products most closely tied to the company.
| Brand or code | Peptide type | Main approved or target use | Status |
|---|---|---|---|
| Zoladex (goserelin) | GnRH agonist decapeptide | Prostate cancer, breast cancer, endometriosis | Marketed by AstraZeneca |
| Byetta / Bydureon (exenatide) | GLP-1 receptor agonist peptide | Type 2 diabetes | Acquired with Amylin in 2012; US promotion wound down |
| Symlin (pramlintide) | Amylin analog | Blood sugar control with mealtime insulin | Acquired with Amylin; no longer actively promoted in the US |
| AZD6234 | Long-acting amylin analog | Obesity and metabolic disease | Investigational — not approved |
| AZD9550 | GLP-1 / glucagon dual agonist peptide | Obesity and metabolic disease | Investigational — not approved |
Goserelin (Zoladex)
Goserelin is a synthetic decapeptide that works as a GnRH agonist, shutting down the hormonal signals that drive certain tumors and endometriosis. It is given as a small implant under the skin of the abdomen, usually once a month or once every three months.
Goserelin has been on the US market for decades and remains the clearest example of an AstraZeneca peptide drug.
Exenatide (Byetta, Bydureon)
Exenatide is a 39-amino-acid GLP-1 receptor agonist originally derived from Gila monster saliva. It reached AstraZeneca through the Amylin acquisition and was later offered as a once-weekly injectable.
AstraZeneca has since stepped back from promoting the exenatide brands in the United States as the GLP-1 market shifted toward newer agents.
Pramlintide (Symlin)
Pramlintide is an amylin analog approved as an add-on to mealtime insulin. It also came with the Amylin deal and is no longer actively promoted in the US.
AstraZeneca's Peptide Pipeline
AstraZeneca's current peptide research is concentrated in obesity and cardiometabolic disease. Recent pipeline disclosures list AZD6234, a long-acting amylin analog, and AZD9550, a dual GLP-1 and glucagon receptor agonist peptide.
The strategy is easy to follow. Amylin analogs such as cagrilintide have shown they can add weight loss on top of GLP-1 therapy, so AstraZeneca wants a position in that combination space rather than competing only with existing GLP-1 drugs.
Investigational means exactly that. These peptides are not FDA-approved, not for sale, and not distributed as AstraZeneca products through compounding pharmacies or anywhere else.
Why Searches for AstraZeneca Peptide Drugs Lead Somewhere Else
Some online sellers use names that sound corporate — astra llc peptides, for example — and shoppers sometimes assume a connection to the pharmaceutical company. There is none. AstraZeneca is a publicly traded drugmaker, and those shops are independent research-chemical vendors.
AstraZeneca is not affiliated with any online store selling research peptides, including BPC-157 or AOD-9604.
The same confusion appears with astraea pharmaceuticals products, a small research-peptide brand whose name is easy to misread. People searching for where to buy bpc-157 peptide often land on pages that borrow a familiar-sounding name to build trust.
A similar brand name is not evidence of testing, purity, or legality. Website design says nothing about what is actually inside a vial.
Prescription Peptides vs. Research Peptides
If you want a dependable peptide drugs list, start with the FDA's approved products database or a pharmacy formulary instead of a search result. That list is shorter than the internet suggests, and every entry has a defined indication, dose, and monitoring plan.
Patients often ask what are peptide drugs used for, and the honest answer depends on the molecule. Goserelin suppresses hormone production, exenatide and pramlintide help manage blood sugar, and GLP-1 peptides are used for type 2 diabetes and weight management.
Research peptides sit in a different category. They are sold "for laboratory research only," are not FDA-approved for human use, and are not manufactured under pharmaceutical quality standards.
Safety and Legal Points to Keep in Mind
- Prescription peptide medicines should only be used under a prescriber's supervision, with routine follow-up.
- BPC-157, AOD-9604, and similar compounds are not FDA-approved drugs for human use in the United States.
- Supplies marketed as bac water for peptide injections are labeled for laboratory or dilution use, and self-injecting any unapproved product carries infection, dosing, and sterility risks.
- Peptides shipped from overseas may be counterfeit, underdosed, or contaminated with unlisted substances.
Talk with a licensed healthcare professional before starting any peptide, and report side effects promptly. For weight loss or a chronic condition, approved therapies with documented risk profiles are the safer starting point.
AstraZeneca's peptide footprint is real but narrow: one long-marketed cancer and hormone therapy, two acquired diabetes products, and a pipeline aimed squarely at obesity.
Frequently Asked Questions
Does AstraZeneca make BPC-157?
No. BPC-157 is not an FDA-approved drug and AstraZeneca does not sell it or any other research peptide. Websites that pair the AstraZeneca name with BPC-157 are relying on brand confusion, and those products are not made, tested, or endorsed by the company.
What peptide drugs does AstraZeneca sell?
Zoladex (goserelin) is AstraZeneca's main marketed peptide medicine, approved for prostate cancer, breast cancer, and endometriosis. The company also acquired exenatide (Byetta, Bydureon) and pramlintide (Symlin) through its 2012 purchase of Amylin Pharmaceuticals, and it has since reduced promotion of those brands in the United States.
Are AstraZeneca peptide drugs FDA-approved and safe?
Approved products such as Zoladex went through FDA review and have known risk profiles that a prescriber reviews with each patient. Research peptides sold online have not gone through that process, so their purity, dosage, and safety are unverified. Anyone considering a peptide medicine should speak with a licensed healthcare professional first.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.